Abstract
To investigate the risk of bleeding events and stroke/systemic embolism (SE) among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial dosage of apixaban and patient age. This retrospective cohort study used de-identified electronic health records based claims data from 314 acute-care hospitals in Japan. NVAF patients newly initiated on warfarin or apixaban, with no prescription during the 180-day blanking period, were eligible. Patients were allocated to receive warfarin or 5 or 2.5 mg twice daily (BID) apixaban. One-to-one propensity-score matching was used to balance patient characteristics between apixaban and warfarin. Among 31,006 eligible patients, 11,972 matched pairs were identified for apixaban versus warfarin. Mean age ± standard deviation was 77.7 ± 10.0 and 77.6 ± 10.0 years and CHADS2 score was 2.2 ± 1.4 and 2.2 ± 1.4 for warfarin and apixaban, respectively. In the apixaban cohort, 39.4% of patients received the standard dose (5 mg BID) and 60.6% received the reduced dose (2.5 mg BID). Incidence rates (events per 100 person-years) of major bleeding, any bleeding and stroke/SE were 3.7, 23.1 and 3.1, and 2.5, 18.6 and 2.0 for warfarin and apixaban cohorts, respectively. Apixaban w...Continue Reading
References
Jul 31, 2007·Journal of the American College of Cardiology·Albert Yuh-Jer ShenWansu Chen
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Aug 6, 2011·Multivariate Behavioral Research·Peter C Austin
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Jul 15, 2016·Journal of the American Heart Association·Xiaoxi YaoPeter A Noseworthy
Oct 30, 2016·Thrombosis and Haemostasis·Gregory Y H LipMelissa Hamilton
Sep 17, 2016·Current Medical Research and Opinion·Craig I ColemanRiccardo Cappato
Nov 28, 2016·Journal of cardiology·Lindsay G S BengtsonAlvaro Alonso
Mar 17, 2017·Thrombosis and Haemostasis·Xiaoyan Shawn LiGregory Y H Lip
May 23, 2017·Heart, Lung & Circulation·Craig I ColemanMatthias Antz
Jun 22, 2017·Current Medical Research and Opinion·Alpesh AminLien Vo
Jun 29, 2017·Stroke; a Journal of Cerebral Circulation·Craig I ColemanMark J Alberts
Jul 1, 2017·Journal of the American College of Cardiology·Tomohiko OnoMasahiro Suzuki
Aug 24, 2017·The Annals of Pharmacotherapy·Giavanna Russo-AlvarezMichael B Rothberg
Aug 30, 2017·Current Medical Research and Opinion·Steven DeitelzweigJay Lin
Aug 31, 2017·Journal of Managed Care & Specialty Pharmacy·Gboyega AdeboyejeRita Redberg
Sep 1, 2017·Current Medical Research and Opinion·Shun KohsakaYasuo Terayama
Oct 5, 2017·Stroke; a Journal of Cerebral Circulation·Myung-Jin ChaGregory Y H Lip
Citations
Jan 15, 2019·Stroke; a Journal of Cerebral Circulation·Matthew M BowerWengui Yu
Jul 25, 2019·Journal of Comparative Effectiveness Research·Sreeram V RamagopalanJaime F de Bobadilla
Dec 4, 2019·Future Cardiology·Ryoko SuzukiLaura McDonald
Apr 29, 2020·Open Heart·Shun KohsakaYasuo Terayama
Nov 21, 2019·Cardiovascular Drugs and Therapy·Yi-Hsin ChanGregory Y H Lip
May 16, 2020·Stroke and Vascular Neurology·Alexander Jacob SweidanWengui Yu
Aug 4, 2018·Korean Circulation Journal·Yan Guang LiGregory Yh Lip
Oct 19, 2019·Research and Practice in Thrombosis and Haemostasis·Matthew A WanatSusan M Abughosh
Oct 28, 2019·Heart Failure Reviews·Zhengbiao XueWengen Zhu
Apr 21, 2020·Clinical Epidemiology·Yasuhisa OnoAtsutaka Yasui
Jul 12, 2019·Journal of Arrhythmia·Hiroshi InoueMasahiro Yasaka
Aug 20, 2019·Journal of cardiology·Hiroshi InoueMasahiro Yasaka
Jun 18, 2021·European Cardiology·Daniel Tt ChongJack Wc Tan
Dec 25, 2021·Frontiers in Pharmacology·Mario GaioAnnalisa Capuano